Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Off-Label Reg Changes For Drugs Could Be Driven By Tobacco Policy

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is eliminating ‘intended use’ regulation requiring firms to label products for unintended use when they have knowledge of such use.


Related Content

US FDA Clarifies ‘Intended Use’ Policy For Approved Products


Related Companies